# AI in Rare Disease Diagnostics Market Size, Share and Trends Analysis 2026 to 2035

**Source:** Google News
**URL:** https://news.google.com/rss/articles/CBMijAFBVV95cUxQblVncnZBek5uR1lkQ2kzME9sdGQxTjBhek42N3g5Sjd6a3Fnd0habVNobmdMQmZHTUtlamdfR2t6OXFEN2tFT2hxRENqMzRkd1VwVnB1bC1uUVRYdnU1QkoydlRKSm9QLTJSZG9TazRLaFhCM2pZeHpXTTNCczdobk52VHR6TlBmZjZHeA?oc=5
**Date:** 2026-01-03

---

Home

Report

Consulting

Market Insights

About Us

Contact Us

Home

Pharmaceuticals

AI In Rare Disease Diagnostics Market Latest Published Study 2026

Report Id: 3386 Pages: 180 Last Updated: 02 January 2026 Format: PDF / PPT / Excel / Power BI

Report Summary

Market Segmentation

Get Free PDF Brochure

Global AI in Rare Disease Diagnostics Market Size is valued at USD 1.7 Bn in 2025 and is predicted to reach USD 19.4 Bn by the year 2035 at a 28.7% CAGR during the forecast period for 2026 to 2035.

The use of sophisticated computational methods like machine learning, deep learning, and natural language processing to recognize, evaluate, and interpret complicated medical data for the early and precise identification of rare diseases is known as artificial intelligence (AI) in rare disease diagnostics. Large volumes of data, such as genetic sequencing data, medical images, electronic health records, and clinical notes, can be processed by AI systems to identify subtle patterns and correlations that are frequently challenging for clinicians to identify because rare disorders are uncommon and present in a variety of ways. The rising incidence of chronic illnesses, the growing need for precision diagnostics, and notable developments in machine learning algorithms that improve diagnostic precision and shorten clinical decision-making times are driving the AI in rare disease diagnostics market's expansion.

Competitive Landscape

Which are the Leading Players in AI in Rare Disease Diagnostics Market?

Deep Genomics

Bayer

Congenica

Enlitic

Face2Gene

BioMind

Fabric Genomics

FDNA

IBM Watson Health

Invitae

Freenome

GeneDx

Mendel.ai

Nostos Genomics

PathAI

SOPHiA GENETICS

Tempus Labs

PhenoTips

Raremark

Market Dynamics

Driver

Growing Need for Early and Accurate Diagnosis of Rare Diseases

The AI in rare disease diagnostics market is primarily driven by the urgent need for early and accurate diagnosis of rare diseases, which frequently have complicated and confusing symptoms. It can take years for traditional diagnostic techniques to produce definitive results, which causes major treatment delays and higher patient morbidity. By quickly evaluating enormous and varied datasets, including genomic, phenotypic, and clinical data, AI-powered systems that make use of cutting-edge machine learning and deep learning techniques are transforming this field. This greatly reduces diagnostic odysseys and improves patient outcomes by allowing clinicians to find illness patterns and correlations that would otherwise go undiscovered. Additionally, the ongoing development of AI algorithms guarantees that diagnostic precision increases with time, solidifying AI's role in identifying uncommon diseases.

Restrain/Challenge

Lack of Representative, High-Quality Data Needed to Develop and Assess Reliable Models

The scarcity of high-quality, representative data required to train and evaluate trustworthy models is a major barrier to the AI in rare disease diagnostics market. Due to the limited patient populations associated with rare diseases, datasets are frequently dispersed between hospitals, nations, and registries, with different formats, missing clinical information, and inconsistent imaging or genomic standards. Additionally, many areas still lack interoperable health records, and stringent privacy regulations and consent requirements can make cross-institution data sharing costly and time-consuming. Due to the "data sparsity" and bias that result from this combination, physicians and regulators are hesitant since AI systems may perform well in one center but fail to generalize to new populations, age ranges, or ethnicities.

Software Segment is Expected to Drive the AI in Rare Disease Diagnostics Market

Genetic Disorders Segment is Growing at the Highest Rate in the AI in Rare Disease Diagnostics Market

In 2024, the genetic disorders segment dominated the AI in rare disease diagnostics market because genetics plays a crucial role in diagnosis, and because inherited uncommon diseases are becoming more common. AI-powered systems are excellent at finding harmful mutations, processing complex genomic data, and linking genotypic data to clinical symptoms. Early diagnosis and treatment of diseases such as muscular dystrophies, uncommon congenital syndromes, and cystic fibrosis are greatly improved by this skill. Additionally, the use of AI in conjunction with next-generation sequencing and genomic data processing has made it possible to identify novel genetic mutations and variants that cause disease with previously unheard-of speed and precision.

Why North America Led the AI in Rare Disease Diagnostics Market?

The AI in rare disease diagnostics market was dominated by North America region in 2024 attributed to the existence of top AI technology firms, significant expenditures in healthcare IT, sophisticated legal frameworks that encourage AI innovation, and the extensive use of electronic health record systems that enable AI integration. Strong cooperation between IT firms and healthcare providers benefits the area by fostering an environment that is favorable to the development and implementation of AI diagnostic solutions.

Additionally, the adoption of AI diagnostic tools is also made possible by the region's strong healthcare infrastructure, high healthcare spending, and significant emphasis on technology innovation. North America is leading the world in the application of AI medical diagnostics due to the implementation of comprehensive AI strategies by major U.S. healthcare systems that include clinical decision support, predictive analytics, and diagnostic imaging.

Key Development

May 2025: Promoter AI, a sophisticated AI program developed by Illumina (US), aids in the interpretation of pathogenic regulatory genetic variations found in noncoding areas of the human genome. This technique is a revolutionary advancement in the detection of rare diseases since it provides a deeper understanding of these conditions.

February 2025: Utilizing cutting-edge machine learning techniques, IT Medical LLC developed the Artificial Intelligence Diagnostics Assistant to improve diagnostic precision and shorten clinical decision-making times for medical professionals in a variety of disciplines.

March 2024: In order to accelerate innovation in healthcare AI applications and improve medical image-based diagnostic technology capabilities, Microsoft Corporation and NVIDIA Corporation announced their partnership to combine Microsoft Azure with NVIDIA DGX Cloud and Clara computing platforms.

October 2023: A unified whole-genome sequencing solution was introduced by Oxford Nanopore Technologies, a UK-based biotechnology company, and Fabric Genomics, an AI-driven US company. By combining speedy sequencing with AI-based variant interpretation, our partnership makes it possible to diagnose uncommon diseases more quickly and accurately. In order to swiftly identify uncommon genetic variants, the technology combines real-time nanopore sequencing with AI-powered genomic analysis. This provides doctors with practical insights that improve diagnostic speed and accuracy, particularly in pediatric treatment.

AI in Rare Disease Diagnostics Market Report Scope :

Report Attribute	Specifications

Market size value in 2025	USD 1.7 Bn

Revenue forecast in 2035	USD 19.4 Bn

Growth Rate CAGR	CAGR of 28.7% from 2026 to 2035

Quantitative Units	Representation of revenue in US$ Bn and CAGR from 2024 to 2034

Historic Year	2022 to 2025

Forecast Year	2026-2035

Report Coverage	The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered	By Component, By Deployment Mode, By Technology, By Application, By End-user, and By Region

Regional Scope	North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope	U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia

Competitive Landscape	Deep Genomics, Bayer, Congenica, Enlitic, Face2Gene, BioMind, Fabric Genomics, FDNA, IBM Watson Health, Invitae, Freenome, GeneDx, Mendel.ai, Nostos Genomics, PathAI, SOPHiA GENETICS, Tempus Labs, PhenoTips, and Raremark

Customization Scope	Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape.

Pricing and Available Payment Methods	Explore pricing alternatives that are customized to your particular study requirements.

Segmentation of AI in Rare Disease Diagnostics Market :

AI in Rare Disease Diagnostics Market by Component

Hardware

Software

Services

AI in Rare Disease Diagnostics Market by Deployment Mode

Cloud-based

On-premise

AI in Rare Disease Diagnostics Market by Technology

Computer Vision

Machine Learning

Natural Language Processing

Deep Learning

Others

AI in Rare Disease Diagnostics Market by Application

Metabolic Disorders

Genetic Disorders

Oncology Disorders

Neurological Disorders

Others

AI in Rare Disease Diagnostics Market by End-user

Hospitals

Diagnostic Centers

Others

AI in Rare Disease Diagnostics Market-By Region

North America-

The US

Canada

Europe-

Germany

The UK

France

Italy

Spain

Rest of Europe

Asia-Pacific-

China

Japan

India

South Korea

South East Asia

Rest of Asia Pacific

Latin America-

Brazil

Argentina

Mexico

Rest of Latin America

Middle East & Africa-

GCC Countries

South Africa

Rest of Middle East and Africa

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Need Customization ?

Frequently Asked Questions

How big is the AI in Rare Disease Diagnostics Market Size?

What is the AI in Rare Disease Diagnostics Market Growth?

Who are the key players in the AI in Rare Disease Diagnostics Market?

What are the key segments of the AI in Rare Disease Diagnostics Market?

Which region is leading the AI in Rare Disease Diagnostics Market?

Get Sample Report

Enquire Before Buying

Schedule Call

Buy Now

Gardasil Market Profit to Sources Report 2025 to 2034

Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.

Category

Pharmaceuticals

Medical Devices

Healthcare IT

Consumer Goods & Services

Agriculture

Semiconductor and Electronics

Technology

Veterinary

Food & Beverages

Packaging

Chemicals and Materials

Biotechnology

Energy and Power

Automotive and Transportation

AI and Digital Technologies

Office Address

Corporate Office :

Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028

Sales Office (U.S.) :

344 Grove St Unit #967 Jersey City, NJ 07302

sale@insightaceanalytic.com

North America:

+1 607 400-7072

Copyrights@ InsightAce Analytic Pvt.Ltd 2025

| Terms & Conditions

| Disclaimer

| Return Policy

| FAQ

---

#news #google-news
